Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 137Parkinson Disease 4, Autosomal Dominant Lewy Body 125Melanoma 95Neoplasms 75Squamous Cell Carcinoma of Head and Neck 65Colorectal Neoplasms 42Triple Negative Breast Neoplasms 38Carcinoma, Renal Cell 37Lung Neoplasms 36Stomach Neoplasms 35Head and Neck Neoplasms 34Breast Neoplasms 34Urinary Bladder Neoplasms 32Neoplasm Metastasis 32Carcinoma, Hepatocellular 32Pancreatic Neoplasms 30Ovarian Neoplasms 29Carcinoma, Transitional Cell 25Endometrial Neoplasms 19Recurrence 16Sarcoma 15Esophageal Neoplasms 15Carcinoma 15Uterine Cervical Neoplasms 14Prostatic Neoplasms 14Small Cell Lung Carcinoma 13Lymphoma 13Fallopian Tube Neoplasms 13Carcinoma, Squamous Cell 13Lymphoma, Non-Hodgkin 12

Interventions

parsaclisib 2MLN 8237 2zanidatamab 1tislelizumab 1tanespimycin 1spartalizumab 1sitravatinib 1pembrolizumab 1pamiparib 1liposomal doxorubicin 1lenvatinib 1epothilone B 1cabiralizumab 1Temozolomide 1Nivolumab 1N-alpha-(2,4,6-triisopropyl-phenylsulfonyl)-3-amidino-(L)-phenyl-alanine-4-ethoxycarbonyl-piperazide hydrochloride 1HMPL-013 1Capecitabine 1AZD7648 11-dodecylpyridoxal 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Advanced Malignancies × pembrolizumab × Clear all
NCT04837196 2025-08-08

Study of ASP7517 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors Expressing WT1 Antigen

Astellas Pharma Inc

Phase 1/2 Completed
24 enrolled 47 charts

Advanced Malignancies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡